Fixed-dose combination
Mometasone furoate and Olopatadine is a fixed-dose combination of a corticosteroid, a histamine-1 receptor antagonist and a histamine-1 receptor inhibitor. It is available as nasal spray. MedsAcross supplies Mometasone furoate and Olopatadine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
RYALTRIS is indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients of age 6 years and older. RYALTRIS is a combination of olopatadine, a histamine-1 (H1)-receptor inhibitor, and mometasone furoate, a corticosteroid, indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older.
Source: US FDA prescribing information
RYALTRIS contains both olopatadine hydrochloride and mometasone furoate. The mechanisms of action described below for the individual components apply to RYALTRIS. Olopatadine Hydrochloride Olopatadine is a histamine-1 (H1) receptor inhibitor. The antihistaminic activity of olopatadine has been documented in isolated tissues, animal models, and humans. Mometasone Furoate Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of inhibitory effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation.
Source: US FDA prescribing information
• Recommended dosage: Adults and Pediatric Patients 12 years of age and older: 2 sprays in each nostril twice daily. Pediatric patients 6 to 11 years of age: 1 spray in each nostril twice daily. • Administration Instructions: For intranasal use only. Prime before initial use by releasing 6 sprays or until a fine mist appears and when it has not been used for 14 or more days by releasing 2 sprays or until a fine mist appears.
Source: US FDA prescribing information
RYALTRIS is contraindicated in patients with known hypersensitivity to any ingredients of RYALTRIS. Hypersensitivity reactions, including wheezing, has occurred after nasal administration of mometasone furoate. Patients with known hypersensitivity to any ingredients of RYALTRIS, including mometasone furoate.
Source: US FDA prescribing information
• Epistaxis, nasal ulcerations, nasal septal perforations, impaired wound healing, and Candida albicans infection: Monitor patients periodically for signs of adverse reactions on the nasal mucosa. • Somnolence: Avoid engaging in hazardous occupations requiring complete mental alertness and motor coordination such as driving or operating machinery when taking RYALTRIS. • Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. • Glaucoma and cataracts: Monitor patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts. • Hypersensitivity Reactions: Hypersensitivity reactions can occur with RYALTRIS.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in labeling: • Local Nasal Adverse Reactions • Somnolence and Impaired Mental Alertness • Glaucoma and Cataracts • Hypersensitivity Reactions • Immunosuppression and Risk of Infections • Hypercorticism and Adrenal Suppression • Effect on Growth The most common adverse reactions (≥1% incidence) are dysgeusia, epistaxis, nasal discomfort, and headache.
Source: US FDA prescribing information
No formal drug-drug interaction studies have been performed with RYALTRIS. The drug interactions of the combination are expected to reflect those of the individual components.
Source: US FDA prescribing information
Storage Store RYALTRIS upright with the purple dust cap on at room temperature. Do not store in a freezer or refrigerator.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Mometasone furoate and Olopatadine, sorted by availability.
| Medicine | Active ingredient | Manufacturer | Register | Availability |
|---|---|---|---|---|
| Ryaltris 25 mcg/665 mcg nasal sprayNasal | Mometasone furoate and Olopatadine | Glenmark PharmaceuticalsIndia | US FDA | Available on request |
1 brand names across 1 markets.
United States
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 13 January 2022 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Mometasone furoate and Olopatadine and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Glenmark Pharmaceuticals.
The catalogue lists 1 brand names for Mometasone furoate and Olopatadine, including Ryaltris.
Yes. The US FDA first approved Mometasone furoate and Olopatadine on 13 January 2022, according to Drugs@FDA.
No listed presentation of Mometasone furoate and Olopatadine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.